Plasma proteome profiling identifies XPNPEP3 as a novel biomarker associated with metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus. This evidence concerns the gene XPNPEP3 and type 2 diabetes mellitus.